

LifeSci Biotechnology Clinical Trials Index

1/27/2020

Effective at the market close on Tuesday, January 28, 2020, ACHN will be removed from the LifeSci Biotechnology Clinical Trials Index and its value will be redistributed to the remaining index components based on their weights.

- On January 27, 2020, FTC approval was granted for Alexion Pharmaceuticals' acquisition of Achillion Pharmaceuticals for \$6.30/share in cash plus a non-tradeable contingent value right.